Flu season ends with a whisper, not a bang.

Published Date: 14 Mar 2023

The 2022-2023 flu season is on the edge of life which has been predicted for half of January and most of February.

Read Full News

Latest News

The Flawed V02 Max Craze

Eric Topol explains the difference between cardiorespiratory fitness and maximal oxygen uptake.

New Adjuvant Option in Node-Positive ER+ Breast Cancer

Dr Kathy Miller evaluates the lidERA trial, comparing adjuvant giredestrant vs standard therapy in node-positive ER+ breast cancer.

Fluticasone-Vilanterol in COPD: Fewer Puffs, Slight Benefit

The use of fluticasone furoate-vilanterol inhalers is tied to slightly better clinical outcomes than the use of budesonide-formoterol or fluticasone propionate-salmeterol inhalers in new COPD users.

Prediabetes Detection: A Critical Lever for Health Systems

Dr Aman Chawla explains why prediabetes detection is a strategic lever for health systems aiming to improve quality and lower total cost of care.

GLP-1 Therapy: Cancer Benefit or Bias?

Dr Maurie Markman examines new data on GLP-1 agonists and cancer risk, which shows promising reductions in several cancers but concerning kidney signals.

The Trade-Offs Behind Life as a GP Locum

Flexibility and autonomy attract many GPs to locum work, but financial volatility and limited career progression complicate the picture.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Latest News

Eric Topol explains the difference between cardiorespiratory fitness and maximal oxygen uptake.

Dr Kathy Miller evaluates the lidERA trial, comparing adjuvant giredestrant vs standard therapy in node-positive ER+ breast cancer.

The use of fluticasone furoate-vilanterol inhalers is tied to slightly better clinical outcomes than the use of budesonide-formoterol or fluticasone propionate-salmeterol inhalers in new COPD users.

Dr Aman Chawla explains why prediabetes detection is a strategic lever for health systems aiming to improve quality and lower total cost of care.

Dr Maurie Markman examines new data on GLP-1 agonists and cancer risk, which shows promising reductions in several cancers but concerning kidney signals.

Flexibility and autonomy attract many GPs to locum work, but financial volatility and limited career progression complicate the picture.

News All Time

Wheelchair Evolution: From Handbikes to Electric Drives

Invented by users and refined by engineers, wheelchairs now span €200 hospital loans to €30,000 custom models — a spectrum that raises clinical, economic and ethical questions.

Vitamin D Unlikely to Improve IBD Disease Activity

Patients with IBD may experience increased serum levels of vitamin D with supplementation, but improvement in disease activity or inflammation remains uncertain.

Study Finds 1 in 3 Patients With IBD Develop Anemia

A global meta-analysis finds that anemia affects 37% of patients with inflammatory bowel disease, highlighting gaps in monitoring and treatment.

Social Media Use Tied to Emotional Issues

The use of digital media, particularly social media, in 2- to 19-year-olds is linked to poor outcomes, including increased depression and lower academic achievement, according to a meta-analysis.

Not Much Gain From Starting TNF Inhibitors Early in axSpA

Starting a TNF inhibitor within 1 year of the onset of back pain may not improve clinical outcomes or drug retention compared with starting therapy after axial spondyloarthritis is established.

Children With Autism Face Multitude of Comorbidities: Study

They also face more disadvantages in multiple social determinants of health such as poverty, food hardship, and lead exposure.

Genomics and AI Will Up Precision of Glaucoma Care

Polygenic risk scores in development for glaucoma could usher in more personalized estimates of risk.

Doctors Argue ‘Provider’ Blurs Clinical Roles

The American College of Physicians says the term ‘provider’ blurs lines between nurse practitioners and physicians, confuses patients, and fails to recognize expertise.

Can Biomarkers Distinguish Psychosis From Depression?

A large international study reports no overlap between the biological signatures of early depression and psychosis.

New Telehealth Standards: The Upshot for Australian Doctors

A consortium of telehealth companies and insurers has published its ‘National Telehealth Standards,’ but some question the document’s impact.

Exercise Frequency, Cadence May Predict White Matter Health

The frequency of physical activity and step cadence may be the top predictors of brain health outcomes in adults aged 40 years or older, new research suggests.

Early Treatment Goes a Long Way for Ulcerative Colitis

In patients with ulcerative colitis, initiation of biologic therapy within 12 months of diagnosis is linked to a lower risk for disease progression than later initiation.

'Concerning': CRC Continues to Shift Toward Younger Adults

Nearly half of new colorectal cancer cases now occur in people younger than age 65 years, highlighting the need for earlier screening and better symptom awareness.

2026-2027 Flu Vaccine Recommendation Covers Subclade K

The agency’s advisors express concern about low vaccine uptake and this season’s mismatched strains.

First-Trimester Oropouche Linked to Brain Malformations

The study ties first-trimester Oropouche infection to severe fetal neurodevelopmental anomalies and urges RT-PCR within 2-7 days plus multiplex arbovirus testing to rule out co-infection.